Published in the journal Age and Ageing, a new systematic review of the current research suggests that anticoagulant drugs may have cognitive benefit for those with AF (atrial fibrillation).
This study will investigate whether early initiation of direct anticoagulant drugs will be as safe as later initiation in stroke patients with an abnormal heart rhythm (atrial fibrillation). It will also investigate whether early initiation could lead to fewer recurrent strokes.
Techniques to predict - and in future prevent - brain haemorrhage in people treated with warfarin after stroke caused by atrial fibrillation
The CROMIS-2 study investigated whether signs of small brain bleeds on routine brain scans can help us understand which ischaemic stroke patients with atrial fibrillation are at increased risk of a bleed in the brain when on anticoagulant ‘blood thinning’ drugs.
Atrial fibrillation is a type of irregular heartbeat that can cause blood clots to form in your heart. Having atrial fibrillation increases your risk of stroke by five times.
You might be prescribed blood-thinning medication to reduce your risk of a TIA or stroke. This guide explains the two types of blood-thinning medication available, antiplatelets and anticoagulants, and how they are used after a stroke or for someone with atrial fibrillation.
People with a type of irregular heartbeat called atrial fibrillation (AF) are five times more likely to have a stroke. This guide explains what AF is diagnosed, how it increases your risk of stroke and how it is treated.
Published online first in the journal Neurology, a new study suggests that people with AF who have an ICH due to their medication have similar outcomes whether they're on a NOAC or a vitamin K antagonist drug.
You might be given blood-thinning medications after you've had a stroke, to help you avoid another one. Or you might need blood-thinning medication if you have a health condition such as a heart problem or blood-clotting disorder which could lead to a stroke.
The European Stroke Organisation Conference (ESOC) 2018 is currently on from 16-18 May in Gothenburg, Sweden. The first day of ESOC included some truly inspiring scientific sessions, including the WAKE-UP trial, RIGHT-2 trial and CROMIS-2 trials.